Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that it will
formally launch and showcase its new Celase® GMP enzyme at the 2015
International Society for Cellular Therapy (ISCT) annual meeting on May
27th to 30th in Las Vegas. This will mark the
first time that Cytori has made Celase® GMP available for purchase as a
standalone product.
Celase® is a proprietary enzyme blend that was designed specifically to
optimize Cytori’s automated adipose tissue dissociation process. Celase®
is produced using avian and mammalian tissue-free raw materials, aseptic
processes and sterile filtration under cGMP guidelines.
“Celase® GMP’s unique, best-in-class formulation is the result of
significant investment made by Cytori,” said Dr. Marc Hedrick, President
and CEO of Cytori Therapeutics. “By making Celase® GMP broadly available
to researchers, we believe Cytori can simultaneously accelerate the cell
therapy field, de-risk clinical implementation and enhance our cash
flows. This represents a clear win-win scenario for all parties.”
Integrating Celase® GMP into cell isolation study protocols can
facilitate a smooth transition from bench and animal research to
downstream clinical applications. Celase® has been approved by the U.S.
FDA for use in clinical trials evaluating Cytori Cell Therapy™ in
patients with chronic heart failure, osteoarthritis of the knee and hand
manifestations of scleroderma.
“Each day our goal is to deliver the best possible health care to our
patients. Using a clinical grade enzyme such as Celase® to generate a
safe and high quality cell output to treat patients helps us attain this
goal,” said Dr. Maurizio Calcagni, Vice Chairman of the Division of
Plastic Surgery and Hand Surgery at University Hospital Zurich.
“Cytori’s new Celase® GMP product will provide researchers with superior
and unparalleled convenience in their lab, clarity in their approach,
and confidence in their results,” said Russ Havranek, Director of Global
Marketing and Sales at Cytori Therapeutics.
ISCT attendees are invited to meet with Cytori representatives at booth
#901 to learn more about Celase® GMP. Researchers may also visit www.celase.com
to be informed of announcements and special offers or send inquiries to celase@cytori.com
about purchasing Celase® GMP directly.
About Cytori Therapeutics, Inc.
Cytori Therapeutics is a late stage cell therapy company developing
laboratory equipment and autologous cell therapies from adipose tissue
to treat a variety of medical conditions. Data from preclinical studies
and clinical trials suggest that Cytori Cell Therapy™ acts principally
by improving blood flow, modulating the immune system, and facilitating
wound repair. As a result, Cytori Cell Therapy™ may provide benefits
across multiple disease states and can be made available to the
physician and patient at the point-of-care through Cytori’s proprietary
technologies and products. For more information, please visit www.cytori.com.
Copyright Business Wire 2015